KR102053730B1 - A novel enterococcus faecalis strain ami-1001 having probiotics activity, and uses thereof - Google Patents
A novel enterococcus faecalis strain ami-1001 having probiotics activity, and uses thereof Download PDFInfo
- Publication number
- KR102053730B1 KR102053730B1 KR1020180097514A KR20180097514A KR102053730B1 KR 102053730 B1 KR102053730 B1 KR 102053730B1 KR 1020180097514 A KR1020180097514 A KR 1020180097514A KR 20180097514 A KR20180097514 A KR 20180097514A KR 102053730 B1 KR102053730 B1 KR 102053730B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- comparative example
- activity
- enterococcus faecalis
- inflammatory
- Prior art date
Links
- 241000194032 Enterococcus faecalis Species 0.000 title claims abstract description 13
- 229940032049 enterococcus faecalis Drugs 0.000 title claims abstract description 13
- 239000006041 probiotic Substances 0.000 title description 16
- 235000018291 probiotics Nutrition 0.000 title description 16
- 230000000694 effects Effects 0.000 title description 13
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 19
- 210000003608 fece Anatomy 0.000 claims abstract description 18
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 39
- 239000002537 cosmetic Substances 0.000 claims description 19
- 235000013376 functional food Nutrition 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000006166 lysate Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000000116 mitigating effect Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 230000000052 comparative effect Effects 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 18
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 230000036541 health Effects 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- -1 trachants Polymers 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 235000020256 human milk Nutrition 0.000 description 8
- 210000004251 human milk Anatomy 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000007760 free radical scavenging Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000194033 Enterococcus Species 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C12R1/46—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Abstract
Description
본 발명은 우수한 생리활성을 보유한 신규 엔테로코커스 패칼리스 균주, 및 이의 용도에 관한 것이다.The present invention relates to novel Enterococcus faecalis strains having good physiological activity, and to their use.
피부는 외부환경과 접촉하여 자극에 대한 신체를 보호하는 가장 기초적인 방어기관이며, 외적인 아름다움을 표현하는 중요한 기관이다.The skin is the most basic defense body that protects the body from stimulation by contact with the external environment and is an important organ that expresses external beauty.
외적인 아름다움이 젊음과 건강을 상징하는 판단의 기준일 뿐 아니라 자신감을 표출하여 업무능력에 영향을 주는 경쟁력으로 자리잡고 있기 때문에, 현대사회에서 피부를 관리하는 경향이 증가하고 있다.The tendency to care for skin in modern society is increasing because external beauty is not only a standard of judgment that symbolizes youth and health, but also has become a competitive force that affects work ability by expressing confidence.
그러나 나이가 들어감에 따라 신진대사를 조절하는 각종 호르몬의 분비가 감소하고, 면역세포의 기능과 세포들의 활성이 저하되어 생체에 필요한 면역 단백질 및 생체 구성 단백질들의 생합성이 줄어들게 되고, 외적으로는 오존층 파괴와 같은 환경오염으로 인한 자외선, 자유 라디칼 및 활성산소의 증가로 인하여 발생하는 물리적, 화학적 자극 및 스트레스로 인한 피부의 정상기능이 약화되고 노화가 촉진되며 혈색이 나빠지고 피부가 주름지게 된다.However, as they age, the secretion of various hormones that regulate metabolism decreases, and the function and activity of immune cells decreases, reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms. Due to the increase of ultraviolet rays, free radicals and free radicals due to environmental pollution, such as physical and chemical stimulation and stress caused by the weakening of the normal function of the skin, accelerated aging, blood color and wrinkles skin.
피부의 최외각층에 존재하는 각질세포(각질형성세포, Keratinocyte)는 섬유아세포, 내피세포 및 진피세포에 주로 있는 면역세포들과 상호작용하여 피부자극반응의 개시, 조정, 조절에 중요한 역할을 한다. 피하의 염증반응과 관련하여 피부자극은 가장 일반적인 유해 효과이며 임상적으로 접촉성 피부염의 70%는 피부자극으로 설명될 수 있다. Keratinocytes (Keratinocytes) in the outermost layer of the skin interact with immune cells, mainly in fibroblasts, endothelial cells and dermal cells, and play an important role in the initiation, control and regulation of skin irritation. Skin irritation is the most common detrimental effect associated with subcutaneous inflammatory reactions, and clinically 70% of contact dermatitis can be explained by skin irritation.
홍반, 부종, 균열, 수분손실, 표피탈락, 간지럼증 및 통증은 자극성 또는 알러지성 접촉성 피부염의 대표적 증상들로서, 세포의 항상성에 이상이 오고 염증반응이 일어나 야기될 수 있다. 상기 증상들은 피부자극에 의해 생겨나는 복잡한 생화학적, 신경과 혈관 세포의 반응들의 연쇄작용에 의한 궁극적 생리학적 소견이다.Erythema, edema, cracks, water loss, epidermis dropouts, epilepsy and pain are typical symptoms of irritant or allergic contact dermatitis, which can cause abnormal cell homeostasis and inflammatory reactions. These symptoms are the ultimate physiological findings by the chain action of the complex biochemical, nerve and vascular cell responses produced by skin irritation.
한편, 프로바이오틱스는 적절량 섭취하였을 때 숙주의 건강에 유익한 효과를 주는 살아있는 미생물로 정의된다.Probiotics, on the other hand, are defined as living microorganisms that, when ingested in appropriate amounts, have a beneficial effect on the health of the host.
지금까지 발견된 프로바이오틱스의 종류는 수 백 개에 이르며, 향후 더 많은 프로바이오틱스가 발견될 수 있다. There are hundreds of probiotics discovered so far, and more probiotics could be discovered in the future.
프로바이오틱스는 살아있으므로 다양한 균의 변이가 가능하다. 이 중에서 우리나라 식품의약품안전처가 건강기능식품에 사용할 수 있는 프로바이오틱스균주로 인정한 것은 크게 5가지(락토바실러스, 비피도박테리움, 락토코커스, 엔테로코커스, 스트렙토코커스)로 구분되고, 종류는 19종에 이른다.Because probiotics are alive, a variety of bacteria can be mutated. Of these, the Ministry of Food and Drug Safety recognized the probiotic strains that can be used in health functional foods.They are divided into five types (Lactobacillus, Bifidobacterium, Lactococcus, Enterococcus, Streptococcus) and 19 kinds. .
구체적으로, 상기 락토바실러스는 락토바실러스 아시도필루스, 락토바실러스 카세이, 락토바실러스 가쎄리, 락토바실러스 불가리큐스, 락토바실러스 헬베티쿠스, 락토바실러스 퍼멘텀, 락토바실러스 파라카세이, 락토바실러스 플란타럼, 락토바실러스 루테리, 락토바실러스 람노서스, 락토바실러스 살리바리우스 종, 상기 비피도박테리움은 비피도박테리움 비피덤, 비피도박테리음 브레베, 비피도박테리음 롱검, 비피도박테리음 락티스 종, 상기 락토코커스는 락토코커스 락티스 종, 상기 엔테로코커스는 엔테로코커스 패칼리스, 엔테로코커스 페시움 종, 상기 스트렙토코커스는 스트렙토코커스 써머필루스 종이 있다.Specifically, the Lactobacillus Lactobacillus asidophilus, Lactobacillus casei, Lactobacillus gaseri, Lactobacillus vulgaris, Lactobacillus helvetus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus luterie, Lactobacillus rhamnosus, Lactobacillus salivarius species, Bifidobacterium, Bifidobacterium bifidem, Bifidobacterium breve, Bifidobacterium longgum, Bifidobacterium lactis species, Said Lactococcus is Lactococcus lactis species, Enterococcus is Enterococcus faecalis, Enterococcus pessium species, Streptococcus is a Streptococcus thermophilus species.
프로바이오틱스 관련 시장을 살펴보면, 2014년 기준 세계 프로바이오틱스 시장규모는 35조원이며 2020년까지 57조원으로 연평균 7.6%의 지속적인 성장을 보일 것으로 예측된다. 국내 프로바이오틱스 시장은 2014년 기준 1500억 원으로 시장 규모가 크지는 않으나, 2013년 대비 250%의 성장률을 보이는 등 시장이 급격히 성장하고 있다.Looking at the probiotic market, the global probiotic market is estimated at KRW35 trillion in 2014 and annual growth of 7.6% annually at KRW57 trillion by 2020. The domestic probiotics market is small in size, with KRW 150 billion as of 2014, but the market is growing rapidly with 250% growth compared to 2013.
현재 해외의 프로바이오틱스에 대한 면역조절 능력의 평가는 다양한 질환 동물모델에 적용되고 있으며, 그 성과 역시 해마다 가파른 속도로 증가하고 있는 단계이다.Currently, the evaluation of immunomodulatory ability against probiotics abroad is applied to various disease animal models, and the achievement is also increasing at a steep rate every year.
당뇨병, 류마티스 관절염, 퇴행성관절염, 궤양성 대장염과 같은 염증성 질환들의 염증 반응 억제를 타겟팅하는 분야만이 아니라, 독감 바이러스나 암과 같은 질병에 대항할 수 있도록 면역 반응을 증대시킬 수 있는 프로바이오틱스의 기능에 대해서도 연구가 활발히 진행 중이다.Not only does it target the suppression of inflammatory responses in inflammatory diseases such as diabetes, rheumatoid arthritis, degenerative arthritis, and ulcerative colitis, but also the ability of probiotics to increase immune responses against diseases such as the flu virus or cancer. Research is also actively underway.
이외에도 알레르기, 천식, 아토피와 같은 질병의 예방 및 치료 목적으로도 프로바이오틱스의 역할 및 그 기능이 많은 주목을 받고 있다.In addition, the role and function of probiotics have attracted much attention for the prevention and treatment of diseases such as allergies, asthma and atopy.
대부분의 프로바이오틱스는 그 유래가 인간의 장 또는 식품이기 때문에 동물모델을 이용한 효능이 입증되면 다른 화학적 약제와 안정성의 입증에 큰 문제가 없다는 장점이 있다.Since most probiotics are derived from human intestines or foods, there is an advantage that there is no big problem in the demonstration of stability with other chemical agents if the efficacy using animal models is proven.
최근 면역조절제로서 프로바이오틱스의 질병 치료 효능이 다양한 임상실험을 통해 검증되고 있는데, 천식, 궤양성 대장염, 관절염 등의 질병이 많이 시도되고 있으며 최근 들어 아토피에 대한 임상시도 및 연구가 가속화 되고 있다.Recently, the efficacy of probiotics as an immunomodulator has been verified through various clinical trials, and many diseases such as asthma, ulcerative colitis, and arthritis have been attempted. Recently, clinical trials and studies on atopy have been accelerated.
본 발명자들은 생리활성이 우수한 신규의 균주를 발굴하고, 이에 기초하여 생체 안전성이 우수한 다양한 제품에 대한 개발 가능성을 제공하고자 하였다.The inventors of the present invention have attempted to discover novel strains with excellent physiological activity and to provide development possibilities for various products having excellent biosafety.
본 발명은 전술한 종래 기술의 문제점을 해결하기 위한 것으로, 본 발명의 목적은 종래 알려진 균주와 비교하여 생리활성이 우수한 신규 엔테로코커스 균주를 제공하는 것이다.The present invention is to solve the above-mentioned problems of the prior art, an object of the present invention is to provide a novel Enterococcus strain excellent in physiological activity compared to the known strain.
본 발명의 일 측면은 항산화, 항염 또는 항균 활성을 가지는 엔테로코커스 패칼리스(Enterococcus faecalis) AMI-1001 균주를 제공한다.One aspect of the present invention provides Enterococcus faecalis AMI-1001 strain having antioxidant, anti-inflammatory or antibacterial activity.
일 실시예에 있어서, 상기 균주는 모유를 섭취하는 유아의 분변에서 분리할 수 있다.In one embodiment, the strain may be isolated from feces of infants who consume breast milk.
일 실시예에 있어서, 상기 균주는 KCCM 80193으로 기탁된 균주일 수 있다.In one embodiment, the strain may be a strain deposited with KCCM 80193.
본 발명의 다른 측면은 상기 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 화장료 조성물을 제공한다.Another aspect of the present invention provides a cosmetic composition comprising the strain, its lysate, its culture or its extract as an active ingredient.
일 실시예에 있어서, 상기 화장료 조성물은 항산화, 항염 또는 항균용일 수 있다.In one embodiment, the cosmetic composition may be for antioxidant, anti-inflammatory or antibacterial.
본 발명의 다른 측면은 상기 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 항염증용 약학적 조성물을 제공한다.Another aspect of the present invention provides a pharmaceutical composition for anti-inflammatory comprising the strain, its lysate, its culture or its extract as an active ingredient.
본 발명의 다른 측면은 상기 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 기능성 식품을 제공한다.Another aspect of the present invention provides a functional food comprising the strain, its lysate, its culture or its extract as an active ingredient.
본 발명의 일 측면에 따른 균주는 생리활성 및 인체 안전성이 우수하므로 다양한 용도로서 활용 가능하다.Strain according to an aspect of the present invention is excellent in physiological activity and human safety can be utilized for various uses.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.It is to be understood that the effects of the present invention are not limited to the above effects, and include all effects deduced from the configuration of the invention described in the detailed description or claims of the present invention.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.The terminology used herein is to select general terms that are currently widely used as possible in consideration of the functions in the present invention, but may vary according to the intention or precedent of the person skilled in the art, the emergence of new technologies and the like. In addition, in certain cases, there is also a term arbitrarily selected by the applicant, in which case the meaning will be described in detail in the description of the invention. Therefore, the terms used in the present invention should be defined based on the meanings of the terms and the contents throughout the present invention, rather than the names of the simple terms.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art. Terms such as those defined in the commonly used dictionaries should be construed as having meanings consistent with the meanings in the context of the related art, and are not construed in ideal or excessively formal meanings unless expressly defined in this application. Do not.
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.The numerical range includes the numerical values defined in the range. All maximum numerical limits given throughout this specification include all lower numerical limits as if the lower numerical limits were clearly written. All minimum numerical limits given throughout this specification include all higher numerical limitations as if the higher numerical limit were clearly written. All numerical limitations given throughout this specification will include all better numerical ranges within the broader numerical range, as the narrower numerical limitations are clearly written.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, examples of the present invention will be described in detail, but the present invention is not limited by the following examples.
본 발명의 일 측면은 항산화, 항염 또는 항균 활성을 가지는 엔테로코커스 패칼리스(Enterococcus faecalis) 균주를 제공한다.One aspect of the invention provides an Enterococcus faecalis strain having antioxidant, anti-inflammatory or antibacterial activity.
상기 “엔테로코커스(Enterococcus) 속” 균주는 장알균이라고 부르며 그람양성이다. 대표종은 엔테로코커스 패칼리스(Enterococcus faecalis)와 엔테로코커스 패시움(Enterococcus faecium)이 있다.The strain " Enterococcus " is called enterococci and is gram positive. The representative species is Enterococcus faecalis ) and Enterococcus faecium .
본 발명자들은 한국인의 대표 유산균을 선발하기 위하여 전국적으로 다양한 분변 시료를 수집하여 유산균을 분석하고 동정 및 특성을 연구한 결과, 모유를 섭취한 유아의 분변에서 분리한 엔테로코커스 패칼리스의 우수한 생리활성을 규명하였다.In order to select representative lactic acid bacteria of Koreans, the present inventors collected various fecal samples from all over the country to analyze lactic acid bacteria and to identify and characterize them. As a result, the excellent physiological activity of Enterococcus faecalis isolated from feces of breastfeeding infants was investigated. It was clarified.
또한, 상기 균주 중 항산화, 항염, 항균 활성이 가장 우수한 균주를 엔테로코커스 패칼리스 AMI-1001로 명명하였으며, 이를 한국미생물보존센터에 2018년 7월 20일자로 기탁하고, 기탁번호 KCCM 80193을 부여받았다.Also, among the strains, strains with the best anti-oxidant, anti-inflammatory and antibacterial activity were named Enterococcus faecalis AMI-1001, which was deposited on July 20, 2018 by the Korea Microorganism Conservation Center and was given accession number KCCM 80193. .
상기 “항산화”는 산화를 억제하는 작용을 의미하는 것으로, 인체는 산화촉 진물질과 산화억제물질이 균형을 이루고 있으나, 여러 가지 요인들로 인하여 이러한 균형 상태를 잃고 산화를 촉진하는 방향으로 기울게 되면, 생체 내에 산화적 스트레스(oxidative stress)가 유발되어 세포손상 및 병리적 질환을 유발할 수 있다.The term "antioxidant" refers to the action of inhibiting oxidation, the human body is in the balance between the antioxidant and antioxidant inhibitors, but due to a variety of factors to lose this balance state and inclined in the direction of promoting oxidation In addition, oxidative stress may be induced in vivo to cause cell damage and pathological diseases.
산화적 스트레스의 직접적 원인이 되는 활성 산소종(reactive oxygen species, ROS)은 화학적으로 불안정하고 반응성이 높아 DNA, 단백질, 지질 및 탄수화물과 같은 여러 생체물질과 쉽게 반응할 수 있으며, 생체 내 고분자들을 공격하여 세포와 조직에 비가역적인 손상을 일으키거나 돌연변이, 세포독성 및 암 등을 초래하게 되고, 노화의 직접적인 원인이 되기도 한다. 상기 활성 산소종을 제거하거나 감소시킴으로써 항산화 효과를 얻어 노화를 방지하고 건강을 유지할 수 있다.Reactive oxygen species (ROS), which are a direct cause of oxidative stress, are chemically unstable and highly reactive, making it easy to react with many biomaterials such as DNA, proteins, lipids, and carbohydrates. This can cause irreversible damage to cells and tissues, mutations, cytotoxicity, and cancer, and it can be a direct cause of aging. By removing or reducing the reactive oxygen species, an antioxidant effect can be obtained to prevent aging and maintain health.
상기 “항염”은 염증을 억제하는 작용을 의미하며, 염증반응의 조절은 매우 복잡한 것으로 알려져 있는데, 이는 생체 내 복구체계의 증강 및 손상을 감소시킨다. 반복되는 조직의 손상이나 재생에 의해 염증반응이 지속되면, 염증관련 세포에서 ROS와 RNS가 과다 생성되고 영구적인 유전자의 변형이 야기될 수 있다. 즉, ROS와 RNS는 생체 내 여러 가지 세포의 작용을 조절하는 염증 반응과 깊이 관련되어 있다.The "anti-inflammatory" refers to the action of inhibiting inflammation, the regulation of the inflammatory response is known to be very complex, which reduces the buildup and damage of the repair system in vivo. If the inflammatory response persists due to repeated tissue damage or regeneration, overproduction of ROS and RNS in inflammatory cells can result in permanent genetic modification. In other words, ROS and RNS are deeply involved in the inflammatory response that regulates the action of various cells in vivo.
상기 균주는 대사산물인 여러 종류의 유기산에 의해 pH를 감소시키면서 식품의 보존성을 증진시킬 수 있으며, 유기산 외에 과산화수소 및 이들이 생산하는 박테리오신이 보존성에 관여할 수 있다.The strain may improve the preservation of food while reducing the pH by various kinds of organic acids, metabolites, hydrogen peroxide and the bacteriocin they produce may be involved in the preservation.
상기 박테리오신은 세균이 생산하는 단백질 또는 단백질계열의 항균물질로 일반적으로 항균 물질 생산 균주 자신과 계통 및 혈통학적으로 유사한 균종으로 제한된 좁은 항균 범위를 나타내며 자신의 유전자로부터 직접 생합성 된다는 점에서 일반 항생 물질과 구분이 되는 천연의 항균성 단백질이다.The bacteriocin is a protein or protein-based antimicrobial material produced by bacteria. In general, the bacteriocins have a narrow antimicrobial range limited to strains that are lineage and lineage similar to those of the antimicrobial production strains themselves, and are biosynthesized directly from their genes. It is a natural antimicrobial protein that can be distinguished.
상기 균주는 항산화 및 항염 활성뿐만 아니라 항균 활성이 우수하며, 특히, 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 효과적으로 억제하므로, 여드름의 치료 용도로서 활용 가능하다.The strain is excellent in antimicrobial activity as well as antioxidant and anti-inflammatory activity, in particular, Propionibacterium Acnes ( Propionibacterium acnes ) effectively inhibits the activity of the acnes , it can be used as a treatment for acne.
본 발명의 다른 측면은 상기 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 화장료 조성물을 제공한다.Another aspect of the present invention provides a cosmetic composition comprising the strain, its lysate, its culture or its extract as an active ingredient.
상기 화장료 조성물은 통상의 방법에 의해 제형화될 수 있다. 피부 외용제의 제형화에 있어서 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 내용을 참조할 수 있고, 화장료 조성물의 제형화에 있어서 International cosmetic ingredient dictionary, 6th ed(The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995)에 개시되어 있는 내용을 참조할 수 있다.The cosmetic composition may be formulated by conventional methods. Reference may be made to the formulations disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, for formulation of external skin preparations, and in International Cosmetic Ingredient Dictionary, 6th ed (The cosmetic, Toiletry and Fragrance Association). , Inc., Washington, 1995).
상기 화장료 조성물은 일반적인 유화 제형 및 가용화 제형으로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등의 화장수; 훼이셜 로션, 바디로션 등의 유액; 영양 크림, 수분 크림, 아이 크림 등의 크림; 에센스; 화장연고; 스프레이; 젤; 팩; 선 스크린; 메이크업 베이스; 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션; 파우더; 클렌징 크림, 클렌징 로션, 클렌징 오일 등의 메이크업 제거제; 또는 클렌징 폼, 비누, 바디워시 등의 세정제로 제형화될 수 있으나 이에 한정되는 것은 아니다. The cosmetic composition may be prepared in a general emulsion formulation and solubilized formulation. For example, lotion, such as a flexible lotion or a nourishing lotion; Latex, such as facial lotion and body lotion; Creams such as nutrition creams, moisture creams and eye creams; essence; Cosmetic ointments; spray; Gels; pack; Sunscreen; Makeup base; Foundations such as liquid type, solid type or spray type; powder; Makeup removers such as cleansing cream, cleansing lotion and cleansing oil; Or it may be formulated as a cleaning agent such as cleansing foam, soap, body wash, but is not limited thereto.
상기 화장료 조성물은 각각의 제형에 있어서 상기 필수성분 외에 제형의 종류 또는 사용 목적 등에 따라 본 발명에 따른 목적을 저해하지 않는 범위 내에서 다른 성분들이 적절히 배합될 수 있다.The cosmetic composition may be appropriately blended with other ingredients within the range of not impairing the object according to the present invention, depending on the kind or purpose of use of the formulation in addition to the essential components in each formulation.
상기 화장료 조성물은 통상적으로 허용 가능한 담체를 포함할 수 있으며, 예컨대 유분, 물, 계면활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition may generally include an acceptable carrier, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be appropriately blended, but is not limited thereto. no.
상기 허용 가능한 담체는 제형에 따라 달리할 수 있다. 예컨대, 연고, 페이스트, 크림 또는 젤로 제형화될 때 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 추출물이 사용될 수 있다.The acceptable carrier may vary depending on the formulation. For example, when formulated into ointments, pastes, creams or gels, as carrier ingredients, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc, zinc oxide or theirs Extracts can be used.
상기 화장료 조성물은 파우더 또는 스프레이로 제형화될 때, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 추출물이 사용될 수 있고, 스프레이의 경우 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진제를 더 포함할 수 있다.When the cosmetic composition is formulated as a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or extracts thereof may be used as a carrier component, and in the case of a spray, chlorofluorohydro It may further include propellants such as carbon, propane, butane or dimethyl ether.
상기 화장료 조성물은 용액 또는 유탁액으로 제형화될 때, 담체 성분으로서 용매, 용해화제, 또는 유탁화제가 사용될 수 있고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-브틸글리콜 오일이 사용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 사용될 수 있다.When the cosmetic composition is formulated into a solution or emulsion, a solvent, solubilizer, or emulsion agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-butylglycol oil may be used, and in particular, cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, fatty acid esters of polyethylene glycol or sorbitan may be used.
상기 화장료 조성물은 현탁액으로 제형화될 때, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리 옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 사용될 수 있다.When the cosmetic composition is formulated as a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
상기 화장료 조성물이 비누로 제형화될 때, 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등이 사용될 수 있다.When the cosmetic composition is formulated as a soap, as a carrier component, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars and the like Can be used.
상기 화장료 조성물은 최종 제품의 품질이나 기능에 따라 업계에서 통상적으로 사용되는 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉 쇄제, 킬레이트화제, 보존제, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 추가적으로 함유할 수 있다.The cosmetic composition is a fatty material, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, and a fragrance, which are commonly used in the industry, depending on the quality and function of the final product. Commonly used in surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion rod blockers, chelating agents, preservatives, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, cosmetics It may additionally contain adjuvants commonly used in the cosmetic or dermatological arts, such as any other ingredient.
다만, 상기 보조제 및 그 혼합 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 영향을 미치지 않도록 적절히 선택할 수 있다.However, the adjuvant and its mixing ratio may be appropriately selected so as not to affect the desirable properties of the cosmetic composition according to the present invention.
본 발명의 다른 측면은 상기 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 항산화 또는 항염증용 약학적 조성물을 제공한다.Another aspect of the present invention provides a pharmaceutical composition for antioxidant or anti-inflammatory comprising the strain, the lysate, the culture or the extract thereof as an active ingredient.
상기 “유효성분으로 포함하는”은 투여하고자 하는 개체에 대한 치료적 또는 예방적 효과를 제공하기에 충분한 양을 포함하는 것을 의미하며, 상기 균주 또는 그 배양액은 인체에 대한 부작용이 없거나 적으므로 당업자가 양적 상한을 적절히 조정할 수 있다. The term "comprising as an active ingredient" means that it contains an amount sufficient to provide a therapeutic or prophylactic effect on the subject to be administered, the strain or its culture medium has no or little side effects to the human body, The upper limit of quantity can be adjusted suitably.
상기 “예방”은 병리학적 현상의 발생 빈도 또는 정도를 감소시키는 모든 행위를 의미한다. 예방은 완전할 수 있으며 또는 부분적일 수도 있다.The term "prevention" means any action that reduces the frequency or extent of pathological phenomena. Prevention can be complete or partial.
상기 “치료”는 치료하고자 하는 대상 또는 세포의 천연 과정을 변경시키기 위하여 임상적으로 개입하는 모든 행위를 의미하며, 임상 병리 상태가 진행되는 동안 또는 이를 예방하기 위하여 수행할 수 있다. 목적하는 치료 효과는 질병의 발생 또는 재발을 예방하거나, 증상을 완화시키거나, 질병에 따른 모든 직접 또는 간접적인 병리학적 결과를 저하시키거나, 전이를 예방하거나, 질병 진행 속도를 감소시키거나, 질병 상태를 경감 또는 일시적 완화시키거나, 예후를 개선시키는 것을 포함할 수 있다.The term "treatment" refers to all actions that are clinically involved in altering the natural process of the subject or cell to be treated, and may be performed during or to prevent a clinical pathology. The desired therapeutic effect may prevent the occurrence or recurrence of the disease, alleviate the symptoms, reduce all direct or indirect pathological consequences of the disease, prevent metastasis, slow the progression of the disease, or Mitigating or temporarily alleviating the condition or improving the prognosis.
상기 조성물은 경구적 전달, 비경구적 전달의 형태로 투여될 수 있다. 상기 트리신은 전신 또는 국소 투여될 수 있으며, 상기 투여는 경구 투여 및 비경구 투여를 포함할 수 있다. 상기 균주 또는 배양액이 조성물로서 투여되는 경우, 적절한 투여 형태를 제공하도록 적합한 양의 약학적으로 허용되는 비히클 또는 담체와 함께 제형화될 수 있다. The composition may be administered in the form of oral delivery, parenteral delivery. The tricine may be administered systemically or topically, and the administration may include oral administration and parenteral administration. When the strain or culture is administered as a composition, it may be formulated with a suitable amount of pharmaceutically acceptable vehicle or carrier to provide a suitable dosage form.
상기 조성물은 약학 조성물의 제조에 사용되는 담체, 부형제 및 희석제를 더 포함할 수 있다.The composition may further comprise a carrier, excipient and diluent used in the manufacture of the pharmaceutical composition.
상기 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유를 들 수 있으나, 이에 제한되는 것은 아니다.The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil, but are not limited thereto.
또한, 상기 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화 하여 사용할 수 있다.In addition, the composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, suppositories, and sterile injectable solutions.
경구 투여를 위한 고형제제는 정제, 환제, 산제, 과립제, 캡슐제 등이 사용될 수 있고, 상기 고형제제는 상기 균주에 적어도 하나 이상의 부형제, 예컨대, 전분, 칼슘카보네이트, 수크로스, 락토오스, 또는 젤라틴 등을 혼합하여 조제할 수 있다. 또한, 상기 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제가 사용될 수 있다.Solid preparations for oral administration may include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, or the like. It can mix and prepare. In addition to the above excipients, lubricants such as magnesium styrate and talc may be used.
경구 투여를 위한 액상 제제는 현탁제, 내용액제, 유제, 시럽제 등이 사용될 수 있고, 단순희석제인 물, 리퀴드 파라핀 외에 여러 가지 부형제, 예컨대 습윤제, 감미제, 방향제, 보존제 등이 사용될 수 있다.As the liquid preparation for oral administration, suspending agents, solvents, emulsions, syrups, and the like may be used, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, and the like, in addition to water and liquid paraffin, which are simple diluents, may be used.
비경구 투여를 위한 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 사용될 수 있다. 상기 비수성용제, 현탁제는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르가 사용될 수 있다. 상기 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴이 사용될 수 있다.For parenteral administration, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories can be used. The non-aqueous solvent and suspension may be propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin may be used.
상기 약학적 조성물은 약제학적으로 유효한 양이 대상체에 투여될 수 있다. 상기 “약제학적으로 유효한 양”은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. The pharmaceutical composition may be administered to a subject in a pharmaceutically effective amount. The term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type of disease, the severity, the activity of the drug, and the drug. Sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
상기 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 바람직하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical compositions may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. In consideration of all the above factors, it is desirable to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
본 발명의 다른 측면은 상기 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 기능성 식품을 제공한다.Another aspect of the present invention provides a functional food comprising the strain, its lysate, its culture or its extract as an active ingredient.
상기 “기능성 식품"은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미한다. 상기 기능성 식품은 그 제형에 있어서 특별히 한정되는 바는 없으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.The term “functional food” means a food prepared and processed using raw materials or ingredients having functional properties useful for the human body. The functional food is not particularly limited in its formulation, and is a health functional food in a general sense. Includes all of them.
상기 건강기능식품은 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, 상기 기능성은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미할 수 있다.The health functional food means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the law on health functional foods, and the functional properties control nutrients or physiologically on the structure and function of the human body. It may mean ingestion for the purpose of obtaining a useful effect for health use such as action.
상기 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 상기 식품 첨가물은 다른 규정이 없는 한 식품의약품 안정처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 적합성 여부를 판단할 수 있다.The health functional food may include a conventional food additive, and unless otherwise specified, the food additive may comply with the standards and standards for the corresponding item according to the General Regulations and General Test Law of the Food Additives Authorized by the Food and Drug Administration. Compliance can be determined by
상기 식품 첨가물 공전에 기재된 품목은 예컨대 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류를 들 수 있다.The items described in the food additive orbital are, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid, natural additives such as color pigments, licorice extract, crystalline cellulose, high pigment, guar gum, sodium L-glutamate preparations, and noodles. Mixed preparations, such as an added alkali, a preservative, and a tar pigment, are mentioned.
상기 건강기능식품은 정제, 과립, 분말, 캅셀, 액상의 용액 및 환으로 이루어진 군에서 선택된 어느 하나의 제형으로 제조 및 가공될 수 있다.The health functional food may be prepared and processed into any one formulation selected from the group consisting of tablets, granules, powders, capsules, liquid solutions and rings.
상기 정제 형태의 건강기능식품은 부형제, 결합제, 붕해제 및 다른 첨가제와의 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축 성형하거나, 상기 혼합물을 직접 압축 성형하여 제조할 수 있다. 또한, 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수 있으며, 필요에 따라 적당한 제피제로 제피할 수도 있다.The health functional food in tablet form may be prepared by granulating a mixture with an excipient, a binder, a disintegrant and other additives in a conventional manner, and then compressing the mixture with a lubricant, or directly compressing the mixture. . In addition, the health functional food in the form of tablets may contain a mating agent and the like, if necessary, may be coated with a suitable coating agent.
상기 캅셀 형태의 건강기능식품 중 경질캅셀제는 통상의 경질캅셀에 부형제 등의 첨가제와의 혼합물 또는 그의 입상물 또는 제피한 입상물을 충진하여 제조할 수 있으며, 연질캅셀제는 트리신 및 부형제 등의 첨가제와의 혼합물을 젤라틴 등 캅셀기제에 충진하여 제조할 수 있다. 상기 연질캅셀제는 필요에 따라 글리세린 또는 솔비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among the health functional foods in the form of capsules, the hard capsules may be prepared by filling a conventional hard capsule with a mixture of additives such as excipients or granular substances or peeled granules thereof, and soft capsules with additives such as tricin and excipients. It can be prepared by filling the mixture with a capsule base such as gelatin. The soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
상기 환 형태의 건강기능식품은 트리신, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 적당한 제피제로 제피를, 또는 전분, 탈크 또는 적당한 물질로 환의를 입힐 수도 있다.The health functional food in the form of a cyclic form may be prepared by molding a mixture of tricin, excipient, binder, disintegrating agent, etc. in a suitable manner, and may be coated with sucrose or other suitable coating agent, or starch, talc or a suitable substance. You can also give a favor.
상기 과립형태의 건강기능식품은 트리신, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다. The granular health functional food can be prepared in a granular form of a mixture of tricin, excipients, binders, disintegrants, etc., and may contain a flavoring agent, a mating agent and the like as necessary.
또한, 상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함할 수 있다. In addition, the definitions of the excipients, binders, disintegrants, glidants, copulation agents, flavoring agents and the like are described in documents known in the art and may include those having the same or similar functions.
이하 실시예를 통해, 본 발명을 더욱 상술하나 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.Through the following examples, the present invention will be described in more detail, but the present invention is not limited by the following examples.
실시예Example : : 프로바이오틱Probiotic 균주 분리 Strain isolate
모유를 섭취하는 신생아 분변에서 유산균을 약 1,000여종 분리하고 무작위로 200여 종을 동정한 결과 이중 35.5%가 엔테로코커스 패칼리스(Enterococcus faecalis)로 확인되었다.About 1,000 species of lactic acid bacteria were isolated from breast milk-fed newborn feces and 200 species were randomly identified. Among them, 35.5% were identified as Enterococcus faecalis .
엔테로코커스 패칼리스(Enterococcus faecalis) 중 항산화, 항염, 항균 활성이 가장 우수한 엔테로코커스 페칼리스 KCCM 80193 균주를 분리하여 본 발명의 신규 균주로 하였다. Enterococcus faecalis ) Enterococcus pecalis KCCM 80193 strains having the best anti-oxidant, anti-inflammatory and antibacterial activity were isolated and used as novel strains of the present invention.
상기 균주를 일반적인 유산균 배양에 사용되는 배지에 호기 또는 혐기 배양을 하였으며 종균 배양을 거친 후 본 배양을 하였다. pH는 중성 또는 약산성, 배양온도는 20 내지 40℃를 유지하면서 1 내지 3 일간 배양하였다.The strain was subjected to aerobic or anaerobic culture in a medium used for cultivation of lactic acid bacteria in general, and then cultured after seed culture. The pH was neutral or weakly acidic, and the culture temperature was maintained for 20 to 40 ° C. for 1 to 3 days.
최종 원료를 기준으로 g(그램)당 균체의 수가 7천 5백억 이상에 이르도록 배양되면 열 처리 후 건조 과정을 거쳐 분말화하였다.When the number of cells per gram (gram) based on the final raw material was incubated to reach more than 750 billion, it was powdered through a drying process after heat treatment.
실시예Example 및 And 비교예Comparative example
분리한 프로바이오틱 균주의 안전성 및 기능성을 검증하고자 하기와 같이 실시예 및 비교예를 설정하였다.Examples and comparative examples were set as follows to verify the safety and functionality of the isolated probiotic strains.
모유를 섭취하는 유아의 분변에서 분리한 균주의 생리활성을 규명하고자, 다양한 환경에서 분리한 균주를 비교예로 설정하였다.In order to examine the physiological activity of the strain isolated from the feces of infants ingesting breast milk, the strain isolated in various environments was set as a comparative example.
실험예Experimental Example 1 : 피부 안전성 시험 1: skin safety test
실시예 및 비교예의 시료에 대한 피부 안전성을 검증하기 위해, 섬유아세포(HDF), 대식세포주(RAW264.7), 각질세포(HaCaT)에 대한 MTT assay 실험을 수행하였다.In order to verify the skin safety of the samples of the Examples and Comparative Examples, MTT assay experiments on fibroblasts (HDF), macrophages (RAW264.7), keratinocytes (HaCaT) was performed.
실시예 및 비교예의 시료를 정제수에 농도별로 각각 현탁한 후, 세포 생존율을 측정하였다.Samples of Examples and Comparative Examples were suspended in purified water for each concentration, and then cell viability was measured.
세포 독성은 MTT{3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide} 시약을 이용하여 세포 생존율을 측정하는 모스만(Mosmann)의 방법을 변형하여 수행하였다.Cytotoxicity was performed by modifying Mosmann's method of measuring cell viability using MTT {3- (4,5-dimethylthiazol-2-yl) -2-5-diphenyltetrazolium bromide} reagent.
섬유아세포(HDF), 대식세포주(RAW264.7), 및 각질세포(HaCaT)를 각각 96-웰 플레이트에 1×104 cells/well의 농도로 분주하여 37℃, 5% CO2에서 48 시간 동안 배양하였다.Fibroblasts (HDF), macrophages (RAW264.7), and keratinocytes (HaCaT) were each dispensed in 96-well plates at a concentration of 1 × 10 4 cells / well for 48 hours at 37 ° C., 5% CO 2 . Incubated.
배양 배지를 제거하고 시료를 농도별로 처리한 배지에 48 시간 동안 배양한 후 배지를 제거하고 PBS(Phosphate buffered saline)로 반복 세척하였다.After removing the culture medium and incubating the sample for 48 hours in a concentration-treated medium, the medium was removed and washed repeatedly with PBS (Phosphate buffered saline).
MTT를 5 mg/mL 로 PBS에 녹여 50 L 첨가하고 37℃, 5%의 CO2 에서 48 시간 동안 배양하였다. DMSO(Dimethyl sulfoxide)를 한 웰(well) 당 100L 넣고, 10 분 동안 교반한 후 540 nm에서 흡광도를 측정하였다. 대조군은 TGF(Transforming Growth Factor) 0.01 μg/ml를 사용하였다.MTT was dissolved in PBS at 5 mg / mL, 50 L was added, and incubated for 48 hours at 37 ° C and 5% CO 2 . 100 L of DMSO (Dimethyl sulfoxide) was added per well, stirred for 10 minutes, and the absorbance was measured at 540 nm. As a control group, 0.01 μg / ml of transforming growth factor (TGF) was used.
측정 결과, 각 시료의 모든 농도에서 세포 독성은 확인되지 않았다. 상기 결과는 상기 시료가 인체에 무해할 뿐만 아니라 인체 안전성이 우수함을 시사한다.As a result, no cytotoxicity was confirmed at all concentrations of each sample. The results suggest that the sample is not only harmless to the human body but also has excellent human safety.
실험예Experimental Example 2 : 간세포에서의 2 in hepatocytes 항산화능Antioxidant activity 시험 exam
HepG2 세포에서의 ROS생성은 fluorescent probe DCFH-DA 방법을 이용하여 측정하였다.ROS generation in HepG2 cells was measured using the fluorescent probe DCFH-DA method.
세포를 96-well black plate에 5×104의 농도로 각 well에 분주하고 독성이 없는 농도로 24시간 동안 처리하였다. Cells were dispensed into each well at a concentration of 5 × 10 4 on a 96-well black plate and treated for 24 hours at a non-toxic concentration.
배지를 제거하고 세포 안으로 도입되지 못한 시료를 PBS 버퍼로 2번 세척한 후, DCFH-DA 250μM를 각 well에 첨가하고 37°C에서 1시간 동안 방치하였다.After the medium was removed and the samples which were not introduced into the cells were washed twice with PBS buffer, 250 μM of DCFH-DA was added to each well and left at 37 ° C. for 1 hour.
세포를 PBS로 3회 세척한 후 HBSS에 희석한 1mM TBHP를 첨가하여 2시간 동안 반응시켰다.The cells were washed three times with PBS and then reacted for 2 hours by adding 1 mM TBHP diluted in HBSS.
세포 내에서 손상을 받아 발생한 ROS의 양은 fluorescent spectrophotometer(Biotek Instrument Inc., Winooski, VT, USA)로 여기파장(excitation wavelength) 485nm 및 방출파장(emission wavelength) 530nm에서 형광 세기(fluorescent intensity)를 측정하였다.The amount of ROS generated by damage to cells was measured using a fluorescent spectrophotometer (Biotek Instrument Inc., Winooski, VT, USA) to measure the fluorescence intensity at excitation wavelength 485 nm and emission wavelength 530 nm. .
TBHP 1mM을 처리하여 산화 스트레스를 유발한 세포에서는 아무것도 처리하지 않은 정상 세포에 비해 ROS의 생성이 증가하였다.In cells treated with 1 mM of TBHP, oxidative stress induced ROS production as compared to normal cells treated with nothing.
반면, 실시예 및 비교예의 시료를 처리한 세포에 TBHP를 처리한 결과 ROS의 생성이 농도 의존적으로 억제되었으며, 특히 실시예의 시료를 처리한 세포의 ROS의 생성이 현저히 감소하였다.On the other hand, when TBHP was treated to the cells treated with the samples of the Examples and Comparative Examples, the production of ROS was inhibited in a concentration-dependent manner.
실험예Experimental Example 3 : 3: DPPHDPPH 측정법을 통한 자유라디칼 소거 활성 평가 Evaluation of free radical scavenging activity through measurement
실시예 및 비교예의 시료를 정제수에 농도별로 현탁하여 자유라디칼 소거 활성(free radical scavenging acticity)을 평가하였다.Samples of Examples and Comparative Examples were suspended in purified water at different concentrations to evaluate free radical scavenging acticity.
DPPH 측정법은 억제제(inhibitor)가 안정한 라디칼 DPPH(2,2-Diphenyl-1-picrylhydrazyl radical)를 소거하여 탈색되는 정도를 540nm에서 흡광도를 측정하는 방법이다.DPPH measurement is a method of measuring the absorbance at 540nm the degree of decolorization by scavenging the stable radical DPPH (2,2-Diphenyl-1-picrylhydrazyl radical).
실시예 및 비교예의 시료를 희석하였다. 각각의 용액 100μL에 5×10-4M의 DPPH(2,2-Diphenyl-1-picrylhydrazyl) 100μL를 넣고 1 분간 교반하였다. 25℃ 인큐베이터에서 30 분간 반응시키고 540nm에서 흡광도를 측정하였다(표 3).Samples of Examples and Comparative Examples were diluted. 100 μL of 5 × 10 −4 M DPPH (2,2-Diphenyl-1-picrylhydrazyl) was added to 100 μL of each solution, followed by stirring for 1 minute. The reaction was carried out for 30 minutes in a 25 ° C. incubator and the absorbance was measured at 540 nm (Table 3).
표 3을 참조하면, 실시예의 시료는 1000μg/ml의 농도에서 자유라디칼 소거능이 현저히 높은 것으로 분석되었다.Referring to Table 3, the sample of the Example was analyzed to have a significantly high free radical scavenging ability at a concentration of 1000 μg / ml.
상기 결과는 모유를 섭취한 유아의 분변에서 분리한 균주가 상대적으로 항산화 활성이 우수함을 시사한다.The results suggest that the strain isolated from feces of infants fed breast milk has a relatively superior antioxidant activity.
실험예Experimental Example 4 : 4 : ABTSABTS 측정법을 통한 자유라디칼 소거 활성 평가 Evaluation of free radical scavenging activity through measurement
실시예 및 비교예의 시료를 정제수에 현탁하여 자유라디칼 소거 활성(free radical scavenging acticity)을 평가하였다.Samples of Examples and Comparative Examples were suspended in purified water to evaluate free radical scavenging acticity.
ABTS 측정법은 항산화제가 청녹색의 라디칼 ABTS(2,2'-azinodi[3-ethlbenzthiazolne-6-sulfonic acid])을 소거하여 무색의 ABTS로 전환되는 정도를 732 nm에서 측정하는 방법이다.ABTS is a measure of the conversion of antioxidants to colorless ABTS at 732 nm by eliminating the blue-green radical ABTS (2,2'-azinodi [3-ethlbenzthiazolne-6-sulfonic acid]).
실시예 및 비교예의 시료를 농도별로 희석하여 라디칼 ABTS 소거능을 측정하였다.Samples of Examples and Comparative Examples were diluted by concentration to measure radical ABTS scavenging ability.
SC50은 라디칼 ABTS의 50% 소거하는 농도이다. SC50의 값이 낮을수록 자유라디칼의 소거 활성이 높은 것을 의미하며, 자유라디칼 소거활성이 높을수록 항산화 효과가 뛰어난 것으로 평가할 수 있다.SC 50 is the concentration that eliminates 50% of the radical ABTS. The lower the value of SC 50, the higher the free radical scavenging activity. The higher the free radical scavenging activity, the better the antioxidant effect.
표 3을 참조하면, 실시예 1 내지 4의 SC50는 비교예 대비 현저히 낮았으며, 이는 실시예 및 비교예 간 항산화 활성에 차이가 있음을 시사한다.Referring to Table 3, SC 50 of Examples 1 to 4 was significantly lower than the comparative example, suggesting that there is a difference in antioxidant activity between the Examples and Comparative Examples.
(1000 (1000
μgμg
/mL)/ mL)
(SC(SC
5050
))
실험예Experimental Example 5 : NO 생성 억제 효과 평가 5: evaluation of the effect of inhibiting NO production
실시예 및 비교예의 항염 효과를 확인하기 위하여, RAW264.7 세포주(ATCC number: CRL-2278)를 이용한 GRIESS 법으로 nitric oxide(NO) 형성 억제력 실험을 실시하였다.In order to confirm the anti-inflammatory effects of the Examples and Comparative Examples, nitric oxide (NO) formation inhibitory experiments were performed by the GRIESS method using RAW264.7 cell line (ATCC number: CRL-2278).
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대 배양하고, 웰 하나에 3×105 개씩 들어가도록 24-웰 플레이트에 넣은 후 24 시간 동안 배양하였다.Specifically, RAW264.7 cells, which are macrophages of mice, were passaged several times and placed in a 24-well plate for 3 × 10 5 in one well, followed by incubation for 24 hours.
농도별로 희석한 실시예 및 비교예의 시료를 함유한 세포 배지로 교체하였다. It was replaced with the cell medium containing the samples of the Examples and Comparative Examples diluted by concentration.
양성 대조군은 NO 생성 억제물질인 2-amino-4-picoline을 5μM로 처리하여 30분 동안 배양하였고, 자극원으로 LPS(Lipopolysaccharide)를 1㎍씩 처리하여 24시간 동안 배양하였다.The positive control group was incubated for 30 minutes by treating 2-amino-4-picoline, a NO production inhibitor, with 5 μM, and incubating with 1 μg of LPS (Lipopolysaccharide) for 24 hours.
상층액을 100μL씩 취해 96-웰 프레이트에 옮기고, GRIESS 용액을 100μL씩 가해 상온에서 10분간 반응시키고, 540nm에서의 흡광도를 측정함으로써 시료의 NO 생성 억제 효과를 판단하였다(표 4).100 μL of the supernatant was taken and transferred to a 96-well plate, 100 μL of the GRIESS solution was added thereto, reacted at room temperature for 10 minutes, and the absorbance at 540 nm was measured to determine the effect of inhibiting NO production of the sample (Table 4).
상기 실험은 3회 반복하였으며, NO 생성이 억제되는 것은 항염 효과가 뛰어난 것으로 평가할 수 있다.The experiment was repeated three times, the inhibition of NO production can be evaluated as excellent anti-inflammatory effect.
실시예의 시료는 비교예와 비교하여 NO 생성율이 현저히 낮았으며 상기 결과는 모유를 섭취한 유아의 분변에서 분리한 균주의 항염 활성이 현저히 우수함을 시사한다.The sample of Example had a significantly lower NO production rate than the comparative example and the results suggest that the anti-inflammatory activity of the strain isolated from feces of infants fed breast milk is remarkably excellent.
실험예Experimental Example 6 : 항균 활성 평가 6: antimicrobial activity evaluation
실시예 및 비교예에서 수득한 시료의 항균 활성을 평가하였다. 공시균으로서 프로피오니박테리움 아크네스(Propionibacterium acnes KCTC 3314)를 사용하였으며 양성 대조군으로서 화학합성 항균제인 에리스로마이신을 사용하였다.The antimicrobial activity of the samples obtained in Examples and Comparative Examples was evaluated. As disclosed sludge bacteria Propionibacterium tumefaciens arc Ness (Propionibacterium acnes KCTC 3314) and erythromycin, a chemical synthetic antimicrobial agent, were used as a positive control.
프로피오니박테리움 아크네스균은 5% sheep blood가 포함된 tryptic soy agar 배지에 striking하여 2 내지 3일 정도 배양하여 미리 준비한 McFaland nephleometer standards 0.5(1% Barum chloride(0.05 mL) + 1% Sulfuric acid(9.95 mL)의 탁도와 동일하게 하면 균의 농도는 1x108 cells/mL이었다.Propionibacterium acne was incubated for 2 to 3 days by striking in tryptic soy agar medium containing 5% sheep blood. 9.95 mL) had the same turbidity as 1 × 10 8 cells / mL.
액체 BHI배지 2ml에 각 시료를 0에서 2000ppm까지 희석한 후, 1x108 cells/mL의 균액 20μL를 접종하여 48시간 동안 배양시켰다.After diluting each sample from 0 to 2000 ppm in 2 ml of liquid BHI medium, 20 μL of 1 × 10 8 cells / mL of the bacterial solution was inoculated and incubated for 48 hours.
혼탁도를 기준으로 성장이 저해된 최소농도를 최저 성장저해농도(MIC)로 정의하였으며, 결과는 하기 표 5와 같다.The minimum concentration at which growth was inhibited on the basis of turbidity was defined as the minimum growth inhibition concentration (MIC), and the results are shown in Table 5 below.
표 5를 참조하면 실시예 1 내지 4의 시료는 양성 대조군인 에리스로마이신과 비교하여 항균 효과가 다소 미흡하였으나, 비교예 1 내지 8과 비교하여 항균 효과가 현저히 우수하였다.Referring to Table 5, the samples of Examples 1 to 4 were slightly inferior in antimicrobial effect compared to erythromycin, which is a positive control, but the antimicrobial effect was remarkably excellent compared to Comparative Examples 1 to 8.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The above description of the present invention is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the invention is indicated by the following claims, and it should be construed that all changes or modifications derived from the meaning and scope of the claims and their equivalents are included in the scope of the invention.
기탁기관명 : 한국미생물보존센터(국외)Depositary Name: Korea Microorganism Conservation Center (overseas)
수탁번호 : KCCM80193Accession number: KCCM80193
수탁일자 : 2018720Deposit Date: 2018720
Claims (7)
상기 균주는 모유를 섭취한 신생아의 분변에서 분리한 것인, 엔테로코커스 패칼리스 AMI-1001 (Enterococcus faecalis AMI-1001) KCCM 80193.As Enterococcus faecalis AMI-1001 KCCM 80193 strain having antioxidant and anti-inflammatory activity,
The strain is isolated from feces of breast-fed newborns, Enterococcus faecalis AMI-1001 KCCM 80193.
상기 조성물은 항산화 및 염증 개선용인 화장료 조성물.The method of claim 4, wherein
The composition is a cosmetic composition for improving antioxidant and inflammation.
A functional food for mitigating or improving inflammation comprising the strain of claim 1, its lysate, its culture or its extract as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180097514A KR102053730B1 (en) | 2018-08-21 | 2018-08-21 | A novel enterococcus faecalis strain ami-1001 having probiotics activity, and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180097514A KR102053730B1 (en) | 2018-08-21 | 2018-08-21 | A novel enterococcus faecalis strain ami-1001 having probiotics activity, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102053730B1 true KR102053730B1 (en) | 2019-12-09 |
Family
ID=68837363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180097514A KR102053730B1 (en) | 2018-08-21 | 2018-08-21 | A novel enterococcus faecalis strain ami-1001 having probiotics activity, and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102053730B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022045637A1 (en) | 2020-08-28 | 2022-03-03 | 주식회사 리비옴 | Antitumor bacterial strain, and composition and method using same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060109253A (en) * | 2005-04-15 | 2006-10-19 | 아사마가세이가부시끼가이샤 | New enterococcus faecalis and antibacterial product thereof |
| KR20060108964A (en) * | 2005-04-14 | 2006-10-19 | 정명준 | Enterococcus faecalis cbt-sl(5), preparation of its culture fluid and composition comprising the same |
| KR20100022309A (en) * | 2008-08-19 | 2010-03-02 | 주식회사 쎌바이오텍 | Composition for preventing and treating acne comprising bacteriocin derived from enterococcus faecalis sl-5 |
| KR20110134151A (en) * | 2010-06-08 | 2011-12-14 | 주식회사 케이씨아이 | Agent for treating or preventing skin inflammatory disease comprising cultures of mixed bacteria, cosmetic composition, and pharmaceutical composition |
-
2018
- 2018-08-21 KR KR1020180097514A patent/KR102053730B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060108964A (en) * | 2005-04-14 | 2006-10-19 | 정명준 | Enterococcus faecalis cbt-sl(5), preparation of its culture fluid and composition comprising the same |
| KR20060109253A (en) * | 2005-04-15 | 2006-10-19 | 아사마가세이가부시끼가이샤 | New enterococcus faecalis and antibacterial product thereof |
| KR20100022309A (en) * | 2008-08-19 | 2010-03-02 | 주식회사 쎌바이오텍 | Composition for preventing and treating acne comprising bacteriocin derived from enterococcus faecalis sl-5 |
| KR20110134151A (en) * | 2010-06-08 | 2011-12-14 | 주식회사 케이씨아이 | Agent for treating or preventing skin inflammatory disease comprising cultures of mixed bacteria, cosmetic composition, and pharmaceutical composition |
Non-Patent Citations (1)
| Title |
|---|
| J. Microbiol. Biotechnol., Vol.18, pp.1308-1316(2008.)* * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022045637A1 (en) | 2020-08-28 | 2022-03-03 | 주식회사 리비옴 | Antitumor bacterial strain, and composition and method using same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101975031B1 (en) | Novel Bifidobacterium longum ATG-F5, and cosmetics composition comprising thereof | |
| KR100847103B1 (en) | Fermented guava composition and use thereof | |
| EP2477637B1 (en) | Probiotic lactobacillus rhamnosus strain and oral and topical uses thereof | |
| US8932579B2 (en) | Biological effects of compositions comprising rosmarinic acid | |
| KR20140128674A (en) | Probiotics of Lactobacillus plantarum HY7714 for skin wrinkle inhibitory and moisurizing effects and use of thereof as skin anti-wrinkle or moisturizing products | |
| CN104277998A (en) | Use and methods for preventing and/or treating oral malodour | |
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR101955111B1 (en) | External composition for soothing effect on the skin comprising an extract of fermented wheat germ | |
| KR102244492B1 (en) | A novel Lactobacillus sp. strain and use thereof | |
| TWI689585B (en) | Novel lactic acid strain and immune activating agent containing novel lactic acid strain | |
| KR102553057B1 (en) | Compositions comprising skin derived lactic acid bacteria having effects of anti-oxidation, anti-inflammation and whitening | |
| KR102039477B1 (en) | Pearl shell mucus filtrate showing anti-aging, anti-oxidative, anti-inflammatory and anti-wrinkle, manufacturing method thereof and cosmetic compositions comprising the same | |
| KR102040972B1 (en) | Novel Bifidobacterium lactis UBC-U04 with anti-skin aging or anti-wrinkle activity, and compositions using the same | |
| KR101770140B1 (en) | Lactobacillus fermentum HK and Phormium tenax Fermented extract Manufactured Using Thereof | |
| KR102421144B1 (en) | Bifidobacterium bifidum EPS DA-LAIM promoting the growth of lactobacillus and polysaccharide therefrom | |
| KR20170128097A (en) | Skin external agent for improving skin wrinkle comprising an extract of fermented wheat germ | |
| KR102053730B1 (en) | A novel enterococcus faecalis strain ami-1001 having probiotics activity, and uses thereof | |
| KR101595959B1 (en) | Composition for preventing, improving or treating allergic dermatitis comprising hot water extract or ferment extract of chestnut inner shell | |
| KR101685121B1 (en) | Skin composition comprising the purified extract of fermented chestnut bur showing anti-aging or anti-inflammatory activity | |
| KR20180071721A (en) | Composition for antioxidant or improving skin wrinkle comprising fermented Cudrania tricuspidata extract | |
| KR101627242B1 (en) | Skin composition comprising the purified extract of fermented chestnut bur for anti-wrinkle or anti-bacterial activity | |
| KR102610934B1 (en) | Composition for hair or scalp comprising lysate of Lactobacillus sakei | |
| JP2011168520A (en) | Lactic acid bacterium having melanogenesis inhibitory action and use thereof | |
| KR20190106439A (en) | Cosmetic composition for skin whitening comprising a mixture of lactic acid bacteria culture | |
| KR20190038702A (en) | Anti-inflammatory agent containing fermented laminaria japonica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |